UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(D)
OF THE SECURITIES EXCHANGE ACT OF 1934
January 24, 2005
---------------------------
Date of Report (Date of earliest event reported)
ELITE PHARMACEUTICALS, INC.
-----------------------------------------------
(Exact name of registrant as specified in its charter)
Delaware 333-45241 22-3542636
------------ ------------- --------------
(State or other jurisdiction (Commission (IRS Employer
of incorporation) File Number) Identification No.)
165 Ludlow Avenue, Northvale, New Jersey 07647
---------------------------------------------------------------
(Address of principal executive offices)
(201) 750-2646
---------------------
(Registrant's telephone number, including area code)
--------------------------------------------------------------------------------
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any of the
following provisions:
[ ] Written communications pursuant to Rule 425 under the Securities Act
(17 CFR 230.425)
[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act
(17 CFR 240.14a-12)
[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the
Exchange Act (17 CFR 240.14d-2(b))
[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the
Exchange Act (17 CFR 240.13e-4(c))
ITEM 5.02. DEPARTURE OF DIRECTORS OR PRINCIPAL OFFICERS; ELECTION OF DIRECTORS;
APPOINTMENT OF PRINCIPAL OFFICERS.
Effective January 24, 2005, Mr. John A. Moore resigned as a director of
the Registrant and a member of its Audit Committee and the Nominating Committee
and Mr. Edward Neugeboren, a designee of the Series A Preferred Stockholders,
was appointed a director of the Registrant. He was appointed by the Board of
Directors to the Audit Committee and the Nominating Committee.
Mr. Neugeboren has been a managing partner of IndiGo Ventures LLC, an
investment-banking firm based in New York since June 2003. From May 2001 to
January 2004, Mr. Neugeboren was a managing partner of Third Ridge Capital
Management, LLC, a U.S. equity hedge fund. Mr. Neugeboren was from October 2000
to April 2001 the chief administrative officer of Sorceron, an emerging Silicon
Alley based media software company. From 1998 to 2000, Mr. Neugeboren was the
chief administrative officer and director of Equity Research Operations at
Lehman Brothers. He was deputy director of Equity Research at UBS Warburg,
formerly Warburg Dillon Read from 1996 to1998 and director of Equity Research
Operations from 1995 to1996. Mr. Neugeboren began his career in 1992 as an
equity research analyst covering the specialty pharmaceuticals industry,
including generic drugs and drug delivery at Dillon, Read & Co., Kidder, Peabody
& Co., and Furman, Selz Inc. Mr. Neugeboren is a director of KineMed, Inc. a
drug development and advanced medical diagnostics company based in San
Francisco, California.
Item 9.01. FINANCIAL STATEMENTS AND EXHIBITS
a) Not applicable.
b) Not applicable.
c) Exhibits
99.1 Press Release dated January 25, 2005.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
Dated: January 25, 2005
ELITE PHARMACEUTICALS, INC.
By: /s/ Bernard Berk
---------------------------
Name: Bernard Berk
Title: Chief Executive Officer
2